Coherus Biosciences appoints Georgia Erbez to Board of Directors

Coherus Oncology, Inc.

Board expanded from 9 to 10 directors; Erbez appointed as Class III director until 2026 annual meeting.
Erbez also named to audit committee; has served as Managing Director of Axiom Financial Partners since 2014.
Non-employee director: receives $50,000 annual cash retainer and option to purchase 54,000 shares vesting over 3 years.
Previous roles include CFO of Harpoon Therapeutics and COO of Walking Fish Therapeutics.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Georgia Erbez

Class III Director

CHRS · Coherus Oncology, Inc.

Effective: 2024-02-20
Filed: February 22, 2024, 6:59 PM ET

On February 20, 2024, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), increased the size of the Board from nine directors to ten directors and approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Georgia Erbez to serve as a Class III director to fill the vacancy created by such increase.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Georgia Erbez was appointed as Class III Director at Coherus Oncology, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On February 20, 2024, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), increased the size of the Board from nine directors to ten directors and approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Georgia Erbez to serve as a Class III director to fill the vacancy created by such increase.

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-001542

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.